Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Significant Decline in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the recipient of a significant decline in short interest in January. As of January 31st, there was short interest totalling 3,400 shares, a decline of 76.7% from the January 15th total of 14,600 shares. Based on an average daily trading volume, of 14,800 shares, the short-interest ratio is presently 0.2 days.

Bavarian Nordic A/S Stock Up 3.6 %

Shares of Bavarian Nordic A/S stock traded up $0.28 during trading hours on Friday, hitting $8.16. 4,142 shares of the company’s stock traded hands, compared to its average volume of 8,568. The company has a market cap of $1.93 billion, a PE ratio of 11.83 and a beta of 1.68. Bavarian Nordic A/S has a twelve month low of $6.86 and a twelve month high of $14.60. The stock has a 50 day simple moving average of $8.85 and a 200-day simple moving average of $10.08.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.